Samsung Bioepis First To File EU Lucentis Rival

Confirms SB11 Ranibizumab Biosimilar Candidate Accepted For Filing By EMA

 
• By Dave Wallace

Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.

Racers
Samsung Bioepis Is First Off The Marks With A Ranibizumab Filing • Source: Shutterstock

More from Biosimilars

More from Products